Angiotensin-converting enzyme inhibition: a landmark advance in treatment for cardiovascular diseases
Author:
Publisher
Oxford University Press (OUP)
Subject
Cardiology and Cardiovascular Medicine
Link
http://academic.oup.com/eurheartjsupp/article-pdf/9/suppl_E/E2/1155005/sum037.pdf
Reference51 articles.
1. Ondetti MA , Rubin B, Cushman DW. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science (1977) 196:441–444.
2. Dahlof B , Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet (2005) 366:895–906.
3. Hansson L , Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, de Faire U, Morlin C, Karlberg BE, Wester PO, Bjorck JE. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet (1999) 353:611–616.
4. Hansson L , Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B, Wester PO, Hedner T, de Faire U. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet (1999) 354:1751–1756.
5. ALLHAT officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA (2002) 288:2981–2997.
Cited by 29 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Association of Renin-Angiotensin-Aldosterone System Inhibitor Usage Patterns with Midterm Amputation-Free Survival after Lower Extremity Bypass for Peripheral Arterial Disease;Annals of Vascular Surgery;2023-01
2. Mechanisms of current therapeutic strategies for heart failure: more questions than answers?;Cardiovascular Research;2022-12-07
3. Development of leachable enalapril tablets by controlled porosity osmotic pump technique; a unique approach to enhance its sustained release effect;Journal of Coatings Technology and Research;2021-10-19
4. Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors;Drugs;2021-06-23
5. Angiotensin‐Converting Enzyme Inhibitors;Burger's Medicinal Chemistry and Drug Discovery;2021-04-26
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3